Lipid Management

Lipid management refers to the management of cholesterol and triglyceride levels in the blood, which are risk factors for cardiovascular disease (CVD). Total cholesterol is a key factor for CVD events however, non-HDLC is the primary target for lipid lowering therapy (NICE-23).

CVD risk can be modified through appropriate management of the blood lipid profile, through promoting healthy lifestyle and/or cholesterol-lowering medications. Lipid management is one of the five NHS clinical priorities requiring accelerated improvement to reducing healthcare inequalities (NHS-E) 

Our lipid management offer

At Imperial College Health Partners we have been working closely with the North West London ICB to: 

  • Support case-finding through our Lipids PCN Pilot programme, which supported 6 PCNS and 4 Trust Lipid clinics to case-find, review and optimise lipid-lowering medicines, focusing on patients with a past CVD event (secondary prevention) or Familial Hypercholesterolaemia
  • Increasing the uptake of novel agents i.e. Bempedoic Acid, PCSK9 Inhibitors and Inclisiran through raising awareness of the AAC-NICE Lipid Management pathway national guidance for lipid management.
  • A Child Parent Screening (CPS) pilot (programme) for diagnosis of FH as part of the 12 month immunisation appointment. This supported the identification of other family members and confirmation of diagnosis through genetic testing.
  • An education series to support Case Finding and patient reviews.

Explore our lipid management resources

Watch our webinar on effective case finding

(including fulfilling PCN DES for Familial Hypercholesterolaemia)

Understand the NWL ICS Lipids guidelines

Review the UCLP Proactive Care searches and frameworks to identify ‘at risk’ patients

Watch Heart UK's introduction to Lipid Management videos

COMING SOON: Watch our webinar on statin intolerance and bempedoic acid

Take a look at our FH FAQs

Explore national lipid management guidance changes

COMING SOON: Watch our webinar on the updated lipid management pathway

(including inclisiran and bempedoic acid)

Explore the NWL ICS FH guidelines

Funding and supply agreement for Inclisirin

Want to find out more about how we can support you with your patient outcomes in CVD?

Back to the Cardiovascular homepage